The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL).
CAR-T cell therapy dramatically reduces treatment-related deaths compared to stem cell transplant in patients with aggressive lymphoma, though high-risk patients may benefit from earlier transplant planning.
In this EBMT registry analysis of 515 R/R LBCL patients, CAR-T demonstrated superior overall survival primarily through dramatically lower non-relapse mortality (7% vs 30%), but patients with high-risk IPI — especially elevated LDH — showed no survival advantage over alloSCT. These findings support early alloSCT preparation for eligible high-risk CART candidates and provide IPI-based treatment selection guidance.
What the study was
- Study design
- Retrospective registry cohort study (EBMT)
- Population
- Relapsed or refractory LBCL patients receiving CART (n=303) or alloSCT (n=212) as ≥3rd-line therapy, registered with EBMT 2016-2021
- Sample size
- 515
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Bone Marrow Transplantation
Why it surfaced
Large EBMT registry study directly informing treatment selection between CAR-T and alloSCT in R/R LBCL. Clinically actionable: elevated LDH is a bedside measurement that identifies patients who may not benefit from CART.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.